IL235337A0 - Treatment of sclerosis by a dose of laquinimod - Google Patents

Treatment of sclerosis by a dose of laquinimod

Info

Publication number
IL235337A0
IL235337A0 IL235337A IL23533714A IL235337A0 IL 235337 A0 IL235337 A0 IL 235337A0 IL 235337 A IL235337 A IL 235337A IL 23533714 A IL23533714 A IL 23533714A IL 235337 A0 IL235337 A0 IL 235337A0
Authority
IL
Israel
Prior art keywords
multiple sclerosis
high dose
treating multiple
laquinimod
dose laquinimod
Prior art date
Application number
IL235337A
Other languages
English (en)
Hebrew (he)
Inventor
Dan Bar-Zohar
Original Assignee
Teva Pharma
Bar Zohar Dan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49514859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL235337(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma, Bar Zohar Dan filed Critical Teva Pharma
Publication of IL235337A0 publication Critical patent/IL235337A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL235337A 2012-05-02 2014-10-26 Treatment of sclerosis by a dose of laquinimod IL235337A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261641389P 2012-05-02 2012-05-02
PCT/US2013/039090 WO2013166166A1 (en) 2012-05-02 2013-05-01 Use of high dose laquinimod for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
IL235337A0 true IL235337A0 (en) 2014-12-31

Family

ID=49514859

Family Applications (1)

Application Number Title Priority Date Filing Date
IL235337A IL235337A0 (en) 2012-05-02 2014-10-26 Treatment of sclerosis by a dose of laquinimod

Country Status (21)

Country Link
US (3) US20130303569A1 (enExample)
EP (1) EP2844255A4 (enExample)
JP (2) JP2015515985A (enExample)
KR (1) KR20150013658A (enExample)
CN (2) CN105832733A (enExample)
AR (1) AR090885A1 (enExample)
AU (1) AU2013256352A1 (enExample)
BR (1) BR112014027010A2 (enExample)
CA (1) CA2870684A1 (enExample)
CL (1) CL2014002935A1 (enExample)
EA (1) EA201492010A1 (enExample)
HK (1) HK1206246A1 (enExample)
IL (1) IL235337A0 (enExample)
MX (1) MX2014013039A (enExample)
PE (1) PE20150161A1 (enExample)
PH (1) PH12014502447A1 (enExample)
SG (1) SG11201406594UA (enExample)
TW (2) TW201804997A (enExample)
UY (1) UY34775A (enExample)
WO (1) WO2013166166A1 (enExample)
ZA (1) ZA201408820B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013055907A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
AU2013214909A1 (en) 2012-02-03 2014-09-18 Teva Pharmaceutical Industries Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNFa therapy
AR090073A1 (es) 2012-02-16 2014-10-15 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CA2884272A1 (en) * 2012-10-12 2014-04-17 Giancarlo Comi Laquinimod for reducing thalamic damage in multiple sclerosis
KR20150091077A (ko) 2012-11-07 2015-08-07 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드의 아민염
JP2016510343A (ja) * 2013-02-15 2016-04-07 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを用いる多発性硬化症の治療
EP2970129A2 (en) 2013-03-14 2016-01-20 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
AR098924A1 (es) * 2013-12-23 2016-06-22 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida
SG11201608674UA (en) * 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
WO2017027512A1 (en) * 2015-08-13 2017-02-16 Teva Pharmaceutical Industries Ltd. Use of laquinimod to treat traumatic brain injury
US20190108912A1 (en) * 2017-10-05 2019-04-11 Iquity, Inc. Methods for predicting or detecting disease
TWI879737B (zh) * 2018-07-20 2025-04-11 德商馬克專利公司 利用經取代胺基-嘧啶化合物治療及預防多發性硬化症之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
US20080118553A1 (en) * 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
BR112012000568A2 (pt) * 2009-06-19 2015-10-06 Teva Pharma tratamento da esclerose múltipla com laquinimod
EP2523668A1 (en) * 2010-01-13 2012-11-21 Ramot at Tel-Aviv University Ltd Treatment of multiple sclerosis
WO2013055907A1 (en) * 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
JP2016510343A (ja) * 2013-02-15 2016-04-07 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを用いる多発性硬化症の治療

Also Published As

Publication number Publication date
ZA201408820B (en) 2016-06-29
PE20150161A1 (es) 2015-02-22
JP2015515985A (ja) 2015-06-04
AR090885A1 (es) 2014-12-10
KR20150013658A (ko) 2015-02-05
US20150265592A1 (en) 2015-09-24
TW201804997A (zh) 2018-02-16
JP2017222691A (ja) 2017-12-21
EP2844255A4 (en) 2015-10-14
MX2014013039A (es) 2015-02-04
HK1206246A1 (en) 2016-01-08
SG11201406594UA (en) 2014-11-27
CL2014002935A1 (es) 2015-03-06
PH12014502447A1 (en) 2015-01-12
US20130303569A1 (en) 2013-11-14
EA201492010A1 (ru) 2015-06-30
EP2844255A1 (en) 2015-03-11
UY34775A (es) 2013-11-29
TW201347762A (zh) 2013-12-01
AU2013256352A1 (en) 2014-11-27
CA2870684A1 (en) 2013-11-07
BR112014027010A2 (pt) 2017-06-27
US20160000775A1 (en) 2016-01-07
WO2013166166A1 (en) 2013-11-07
CN104284663A (zh) 2015-01-14
CN105832733A (zh) 2016-08-10

Similar Documents

Publication Publication Date Title
ZA201408820B (en) Use of high dose laquinimod for treating multiple sclerosis
SI2879672T1 (sl) Kombinirana terapija za zdravljenje multiple skleroze
KR102297388B9 (ko) 대사장애를 치료하기 위한 아커만시아의 용도
IL237138A0 (en) Methods of administration of pirfenidone therapy
IL252547A0 (en) Treatment of multiple sclerosis using laquinimod
HUE032919T2 (hu) Azaindazol- vagy diazaindazol-típusú származékok fájdalom kezelésére
LT2857019T (lt) Išsėtinės sklerozės gydymo būdas
SG11201405766SA (en) Methods for increasing efficacy of cd37-based therapy
IL227972A0 (en) Use of glycopyrrolate to treat tachycardia
IL240014A0 (en) Treatment of multiple sclerosis using laquinimod
SMT201900473T1 (it) Formulazione per il trattamento dell’ibs
PL3524260T3 (pl) Kompozycje farmaceutyczne do leczenia braku apetytu
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
HUE044796T2 (hu) Gyógyászati készítmény hiperkoleszterinémia kezelésére
GB201214877D0 (en) Compounds for treatments of tumors
IL236718A (en) Vegfr-3 inhibitors for the preparation of drugs for the treatment of liver carcinoma
IL244620A0 (en) A drug combination including laquinimod for the treatment of multiple sclerosis
ZA201409502B (en) Composition for treatment of warts
IL236870B (en) History of hydroxystatin for the treatment of osteoarthritis
HK1225291A1 (en) Laquinimod combination therapy for treatment of multiple sclerosis
HUE039044T2 (hu) Gyógyászati kompozíció sclerosis multiplex kezelésére
IL228464A (en) Quinolone analogues for use in the preparation of MS drugs